Lack of placental transfer of certolizumab pegol during pregnancy: Results from CRIB, a prospective, postmarketing, multicenter, pharmacokinetic study

Abstract

Introduction: There is a need for effective and safe treatment during pregnancy in women with chronic inflammatory diseases (rheumatoid arthritis/axial spondyloarthritis/psoriatic arthritis/Crohn's disease). Adequate disease control is crucial to reduce the risk of adverse pregnancy outcomes. Anti-TNFs are effective therapies, but because most cross the placenta they are often stopped during pregnancy. Certolizumab pegol (CZP), due to its Fc-free molecular structure, is not expected to undergo placental transfer compared to other anti-TNFs.